CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) had its price target hoisted by equities researchers at Truist Financial from $100.00 to $120.00 in a report issued on Wednesday,Benzinga reports.

Bank stocks have had a solid January, and regional-bank stocks, and the ETF, look set to rise for the rest of the year.

Equitable (NYSE:EQH – Get Free Report) had its price target hoisted by research analysts at Truist Financial from $52.00 to ...

In a report released today, Michael Roxland from Truist Financial maintained a Hold rating on Berry Global Group (BERY – Research Report), with ...

In a report released today, Michael Ciarmoli from Truist Financial maintained a Hold rating on Triumph Group (TGI – Research Report), with a ...

Truist Financial's Q4 earnings exceeded expectations, driven by higher investment banking fees and improved credit trends, with credit provisions down $100M year-over-year. Despite strong Q4 ...

Truist Financial is a leading U.S. commercial bank with a significant presence in the Southeast and Mid-Atlantic regions. As a top-10 bank in the U.S., it benefits from a strong market position in ...

He has covered financial services stocks for more than 20 years. He is also a member of the Argus Investment Policy Committee and Senior Portfolio Group, and frequently appears in print and ...

Fintel reports that on January 7, 2025, Truist Securities initiated coverage of Citizens Financial Group (NYSE:CFG) with a Hold recommendation. Analyst Price Forecast Suggests 14.93% Upside As of ...

Charlotte-based Truist Financial Corp. (NYSE ... payments and a new governance and controls group. “Beau’s knowledge and purpose-driven commitment have been invaluable in guiding our clients ...

Fintel reports that on January 7, 2025, Truist Securities initiated coverage of Citizens Financial Group, Inc. - Preferred Security (NYSE:CFG.PRH) with a Hold recommendation. There are 46 funds or ...